

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
25 May 2023 (25.05.2023)



(10) International Publication Number  
**WO 2023/089564 A1**

(51) International Patent Classification:

*C07K 14/705* (2006.01) *A61K 48/00* (2006.01)  
*A61K 38/17* (2006.01) *A61P 27/02* (2006.01)  
*A61K 9/00* (2006.01) *C12N 15/861* (2006.01)

(21) International Application Number:

PCT/IB2022/061158

(22) International Filing Date:

18 November 2022 (18.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/281,190 19 November 2021 (19.11.2021) US

(71) Applicant: **JANSSEN BIOTECH, INC.** [US/US];  
800/850 Ridgeview Drive, Horsham, Pennsylvania 19044  
(US).

(72) Inventor: **ROGERS, Adam**; 800 South Street, Suite 600,  
Waltham, Massachusetts 02453 (US).

(74) Agent: **LANE, David A.** et al.; JOHNSON & JOHNSON,  
One Johnson & Johnson Plaza, New Brunswick, New Jersey  
08933 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,

(54) Title: METHOD OF TREATING GEOGRAPHIC ATROPY WITH A GENE THERAPY VECTOR EXPRESSING SOLUBLE CD59




Figure 2

(57) Abstract: The described invention provides method for treating a complement disorder such as age-related macular degeneration (AMD) in a subject, comprising administering a pharmaceutical composition into an affected eye of a subject by ocular injection, wherein the composition comprises a nucleic acid encoding a soluble CD59 (sCD59) protein operably linked to a promoter, wherein the nucleic acid encoding sCD59 is packaged into a delivery vector and wherein the administering results in expression and secretion of the sCD59 protein by cells of the affected eye and the expression results in treatment of affected cells in the affected eye.

[Continued on next page]

DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,  
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,  
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*